HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cescato, R. Articles by Reubi, J. C. Search for Related Content PubMed PubMed Citation Articles by Cescato, R. Articles by Reubi, J. C.

Internalization of sst₂, sst₃, and sst₅ Receptors: Effects of Somatostatin Agonists and Antagonists

¹ Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland; ² Institute of Pharmacology and Toxicology, Otto-von-Guericke University, Magdeburg, Germany; ³ Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, California; ⁴ Nuklearmedizinische Klinik und Poliklinik, Technical University of Munich, Munich, Germany; ⁵ Endocrine Research, Beaufour-Ipsen Group, Milford, Massachusetts; ⁶ Division of Radiological Chemistry, University Hospital, Basel, Switzerland; and ⁷ Department of Integrative Biology and Pharmacology, University of Texas Health Science Center–Houston, Houston, Texas

Correspondence: For correspondence or reprints contact: Jean Claude Reubi, MD, Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, P.O. Box 62, Murtenstrasse 31, CH-3010 Berne, Switzerland. E-mail: reubi{at}patho.unibe.ch

The uptake of radiolabeled somatostatin analogs by tumor cells through receptor-mediated internalization is a critical process for the in vivo targeting of tumoral somatostatin receptors. In the present study, the somatostatin receptor internalization induced by a variety of somatostatin analogs was measured with new immunocytochemical methods that allow characterization of trafficking of the somatostatin receptor subtype 2 (sst₂), somatostatin receptor subtype 3 (sst₃), and somatostatin receptor subtype 5 (sst₅) in vitro at the protein level. Methods: Human embryonic kidney 293 (HEK293) cells expressing the sst₂, sst₃, or the sst₅ were used in a morphologic immunocytochemical internalization assay using specific sst₂, sst₃ and sst₅ antibodies to qualitatively and quantitatively determine the capability of somatostatin agonists or antagonists to induce somatostatin receptor internalization. In addition, the internalization properties of a selection of these agonists have been compared and quantified in sst₂-expressing CHO-K1 cells using an ELISA. Results: Agonists with a high sst₂-binding affinity were able to induce sst₂ internalization in the HEK293 and CHO-K1 cell lines. New sst₂ agonists, such as Y-DOTA-TATE, Y-DOTA-NOC, Lu-DOTA-BOC-ATE (where DOTA is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; TATE is [Tyr³, Thr⁸]-octreotide; NOC is [1-NaI³]-octreotide; and BOC-ATE is [BzThi³, Thr⁸]-octreotide), iodinated sugar-containing octreotide analogs, or BIM-23244 were considerably more potent in internalizing sst₂ than was DTPA-octreotide (where DTPA is diethylenetriaminepentaacetic acid). Similarly, compounds with high sst₃ affinity such as KE108 were able to induce sst₃ internalization. In sst₂- or sst₃-expressing cell lines, agonist-induced receptor internalization was efficiently abolished by sst₂- or sst₃-selective antagonists, respectively. Antagonists alone had no effect on sst₂ or sst₃ internalization. We also showed that somatostatin-28 and somatostatin-14 can induce sst₅ internalization. Unexpectedly, however, potent sst₅ agonists such as KE108, BIM-23244, and L-817,818 were not able to induce sst₅ internalization under the same conditions. Conclusion: Using sensitive and reproducible immunocytochemical methods, the ability of various somatostatin analogs to induce sst₂, sst₃, and sst₅ internalization has been qualitatively and quantitatively determined. Whereas all agonists triggered sst₂ and sst₃ internalization, sst₅ internalization was induced by natural somatostatin peptides but not by synthetic high-affinity sst₅ agonists. Such assays will be of considerable help for the future characterization of ligands foreseen for nuclear medicine applications.

Key Words: somatostatin receptors • receptor internalization • antagonist • tumor targeting • receptor immunocytochemistry

Related articles in JNM:

This Month in JNM

JNM 2006 47: 7a-8a. [Full Text]  

This article has been cited by other articles:

				B. Waser, M.-L. Tamma, R. Cescato, H. R. Maecke, and J. C. Reubi Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues J. Nucl. Med., June 1, 2009; 50(6): 936 - 941. [Abstract] [Full Text] [PDF]

				S. Lesche, D. Lehmann, F. Nagel, H. A. Schmid, and S. Schulz Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Trafficking in Vitro J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 654 - 661. [Abstract] [Full Text] [PDF]

				J. C. Reubi and H. R. Maecke Peptide-Based Probes for Cancer Imaging J. Nucl. Med., November 1, 2008; 49(11): 1735 - 1738. [Abstract] [Full Text] [PDF]

				S. Bhandari, N. Watson, E. Long, S. Sharpe, W. Zhong, S.-Z. Xu, and S. L. Atkin Expression of Somatostatin and Somatostatin Receptor Subtypes 1-5 in Human Normal and Diseased Kidney J. Histochem. Cytochem., August 1, 2008; 56(8): 733 - 743. [Abstract] [Full Text] [PDF]

				M. Ginj, H. Zhang, K.-P. Eisenwiener, D. Wild, S. Schulz, H. Rink, R. Cescato, J. C. Reubi, and H. R. Maecke New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting Clin. Cancer Res., April 1, 2008; 14(7): 2019 - 2027. [Abstract] [Full Text] [PDF]

				E. Peverelli, G. Mantovani, D. Calebiro, A. Doni, S. Bondioni, A. Lania, P. Beck-Peccoz, and A. Spada The Third Intracellular Loop of the Human Somatostatin Receptor 5 Is Crucial for Arrestin Binding and Receptor Internalization after Somatostatin Stimulation Mol. Endocrinol., March 1, 2008; 22(3): 676 - 688. [Abstract] [Full Text] [PDF]

				R. Cescato, T. Maina, B. Nock, A. Nikolopoulou, D. Charalambidis, V. Piccand, and J. C. Reubi Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting J. Nucl. Med., February 1, 2008; 49(2): 318 - 326. [Abstract] [Full Text] [PDF]

				G. Tulipano and S. Schulz Novel insights in somatostatin receptor physiology Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S3 - S11. [Abstract] [Full Text] [PDF]

				C. Armani, E. Catalani, A. Balbarini, P. Bagnoli, and D. Cervia Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages J. Leukoc. Biol., March 1, 2007; 81(3): 845 - 855. [Abstract] [Full Text] [PDF]

				M. Duran-Prado, C. Bucharles, B. J. Gonzalez, R. Vazquez-Martinez, A. J. Martinez-Fuentes, S. Garcia-Navarro, S. J. Rhodes, H. Vaudry, M. M. Malagon, and J. P. Castano Porcine Somatostatin Receptor 2 Displays Typical Pharmacological sst2 Features but Unique Dynamics of Homodimerization and Internalization Endocrinology, January 1, 2007; 148(1): 411 - 421. [Abstract] [Full Text] [PDF]

				M. Ginj, H. Zhang, B. Waser, R. Cescato, D. Wild, X. Wang, J. Erchegyi, J. Rivier, H. R. Macke, and J. C. Reubi Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors PNAS, October 31, 2006; 103(44): 16436 - 16441. [Abstract] [Full Text] [PDF]

				L. Bodei, G. Paganelli, and G. Mariani Receptor Radionuclide Therapy of Tumors: A Road from Basic Research to Clinical Applications J. Nucl. Med., March 1, 2006; 47(3): 375 - 377. [Full Text] [PDF]